OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity

• DOI: 10.1212/wnl.0b013e3182a2ca4d
• Publication Date: 2013-07-27T07:29:05Z
• Authors: Michael B. Chance...; Vaishali Patel; Wendy W. Leng; Patrick J. Shenot; Wayne Lam; Denise R. Globe; Alex L. Loeb; Christopher R. Ch...
• Keywords: Adult; Male; Urinary Bladder, Overactive; Middle Aged; 3. Good health; 03 medical and health sciences; Treatment Outcome; Urinary Incontinence; 0302 clinical medicine; Patient Satisfaction; Surveys and Questionnaires; Quality of Life; Humans; Female; Botulinum Toxins, Type A; Urinary Bladder, Neurogenic; Aged

To evaluate the effects of onabotulinumtoxinA on patient-reported outcomes including health-related quality life (HRQOL), treatment satisfaction, and goal attainment in patients with urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO).In this multicenter, double-blind, randomized, placebo-controlled, phase III, 52-week study (ClinicalTrials.gov NCT00311376), UI NDO who were not adequately managed anticholinergic therapy treated intradetrusor injections (200 or 300 U) placebo (0.9% saline). HRQOL measures included Incontinence Quality Life (I-QOL) Questionnaire total score, 3 domain scores (avoidance limiting behavior, psychosocial, social embarrassment), modified Overactive Bladder Patient Satisfaction Treatment (OAB-PSTQ), Global Assessment. Assessments made at baseline, posttreatment week 6 (primary time point), 12, 12-week intervals.Patients (mean age 46 years 30.5 weekly episodes baseline) randomized receive (n = 149) U [n 135] 132]). At 6, improvements from baseline I-QOL score greater (p < 0.001) both onabotulinumtoxinA-treated groups vs placebo. Responses OAB-PSTQ also demonstrated mean 6. Patients received reported improvement Assessment than those group ≤ 0.001 placebo).Patients satisfaction consistently across several outcome instruments.This provides Class I evidence that can improve therapy.